• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

临床革兰氏阴性和革兰氏阳性细菌菌株对磷霉素的敏感性评估及其在感染治疗中的意义。

Assessment of the Susceptibility of Clinical Gram-Negative and Gram-Positive Bacterial Strains to Fosfomycin and Significance of This Antibiotic in Infection Treatment.

作者信息

Kowalska-Krochmal Beata, Mączyńska Beata, Rurańska-Smutnicka Danuta, Secewicz Anna, Krochmal Grzegorz, Bartelak Małgorzata, Górzyńska Aleksandra, Laufer Klaudyna, Woronowicz Krystyna, Łubniewska Joanna, Łappo Jolanta, Czwartos Magdalena, Dudek-Wicher Ruth

机构信息

Department of Pharmaceutical Microbiology and Parasitology, Faculty of Pharmacy, Wroclaw Medical University, Borowska 211, 50-556 Wroclaw, Poland.

Department of Laboratory Diagnostics, Jan Mikulicz-Radecki University Teaching Hospital, Borowska 213, 50-556 Wrocław, Poland.

出版信息

Pathogens. 2022 Nov 30;11(12):1441. doi: 10.3390/pathogens11121441.

DOI:10.3390/pathogens11121441
PMID:36558775
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9786176/
Abstract

Multidrug resistance of bacteria has prompted intensive development work on new medicines, but also the search for effective options among the oldest antibiotics. Although intravenous fosfomycin (IVFOS) seems to be an interesting proposal, the recommended agar dilution method for susceptibility determination poses a major problem in routine diagnostic testing. As a consequence, there is a lack of comprehensive data on the frequency of isolation of susceptible or resistant strains. This fact triggered the disposition of EUCAST concerning the revision of IVFOS breakpoints (BPs), including withdrawal of BPs for (excluding ) and coagulase-negative staphylococci. Therefore, the aim of this study was to assess the activity of fosfomycin against numerous clinical strains using recommended methods. : A total of 997 bacterial strains were tested from the following genera: , spp., spp., spp., and spp., for which there are currently no BPs. The strains were isolated from various clinical materials from patients hospitalized in five hospitals. During the investigation, the recommended agar dilution method was used. Susceptibility to other antibiotics and resistance mechanisms were determined using an automatic method (Phoenix) the disk diffusion method, and E-tests. MIC values of fosfomycin were estimated for all strains and for susceptible and multidrug-resistant (MDR) strains individually. : Except for and , 83% of the strains were susceptible to IVFOS, including the largest percentage of and . spp. turned out to be the least susceptible strains (66%). The highest proportion of susceptibility to fosfomycin was found among strains that were sensitive to other antibiotics (80.9%), and the lowest was found among Gram-negative carbapenemase-producing bacteria (55.6%) and ESBL+ bacteria (61.6%). The MIC evaluation revealed the lowest MIC and MIC values for (0.5 mg/L and 1 mg/L, respectively) and (4 mg/L and 32 mg/L, respectively). The highest values of MIC were found for spp. (256 mg/L), while the highest values of MIC were found for spp. and spp. (256 mg/L and 512 mg/L, respectively). : IVFOS appears to be suitable for the treatment of many infections, including the empirical treatment of polymicrobial infections and those caused by MDR strains, since the sensitivity of the studied strains to this antibiotic in different groups ranged from 66% to as much as 99%. Sensitivity to fosfomycin was also demonstrated by 60% of carbapenem-resistant strains; therefore, IVFOS is one of the few therapeutic options that can be effective against the most resistant Gram-negative rods. In light of the general consultation posted by EUCAST, obtaining data such as IVFOS MIC value distributions may be vital for the decision of implementing fosfomycin into breakpoint tables.

摘要

细菌的多重耐药性促使人们大力研发新型药物,同时也促使人们在最古老的抗生素中寻找有效的选择。尽管静脉注射磷霉素(IVFOS)似乎是一个有趣的提议,但推荐的用于药敏测定的琼脂稀释法在常规诊断测试中带来了一个重大问题。因此,缺乏关于敏感或耐药菌株分离频率的全面数据。这一事实引发了欧洲抗菌药物敏感性试验委员会(EUCAST)对IVFOS折点(BPs)进行修订的决定,包括撤销针对[具体菌种](不包括[具体菌种])和凝固酶阴性葡萄球菌的BPs。因此,本研究的目的是使用推荐方法评估磷霉素对众多临床菌株的活性。:共对来自以下菌属的997株细菌进行了测试:[具体菌属1]、[具体菌属2]菌、[具体菌属3]菌、[具体菌属4]菌和[具体菌属5]菌,目前尚无针对这些菌属的BPs。这些菌株是从五家医院住院患者的各种临床材料中分离出来的。在调查过程中,使用了推荐的琼脂稀释法。使用自动方法(Phoenix)、纸片扩散法和E试验测定对其他抗生素的敏感性和耐药机制。分别估计了所有菌株以及敏感和多重耐药(MDR)菌株的磷霉素MIC值。:除了[具体菌种1]和[具体菌种2]外,83%的菌株对IVFOS敏感,其中[具体菌种3]和[具体菌种4]的比例最高。[具体菌属5]菌被证明是最不敏感的菌株(66%)。对其他抗生素敏感的菌株中对磷霉素敏感性比例最高(80.9%),而在产碳青霉烯酶的革兰氏阴性菌(55.6%)和产超广谱β-内酰胺酶(ESBL+)细菌(61.6%)中比例最低。MIC评估显示[具体菌种6]的MIC和MIC值最低(分别为0.5 mg/L和1 mg/L)以及[具体菌种7](分别为4 mg/L和32 mg/L)。[具体菌属8]菌的MIC值最高(256 mg/L),而[具体菌属9]菌和[具体菌属10]菌的MIC值最高(分别为256 mg/L和512 mg/L)。:IVFOS似乎适用于治疗许多感染,包括对多种微生物感染和由MDR菌株引起的感染进行经验性治疗,因为所研究的不同组菌株对这种抗生素的敏感性范围从66%到高达99%。60%的耐碳青霉烯菌株也对磷霉素敏感;因此,IVFOS是少数几种可能对最耐药的革兰氏阴性杆菌有效的治疗选择之一。鉴于EUCAST发布的总体咨询意见,获取诸如IVFOS MIC值分布等数据对于将磷霉素纳入折点表的决策可能至关重要。

相似文献

1
Assessment of the Susceptibility of Clinical Gram-Negative and Gram-Positive Bacterial Strains to Fosfomycin and Significance of This Antibiotic in Infection Treatment.临床革兰氏阴性和革兰氏阳性细菌菌株对磷霉素的敏感性评估及其在感染治疗中的意义。
Pathogens. 2022 Nov 30;11(12):1441. doi: 10.3390/pathogens11121441.
2
[Evaluation of In vitro Efficacy of Meropenem/Colistin and Meropenem/Fosfomycin Combinations on Multidrug Resistant Gram-Negative Bacilli].美罗培南/黏菌素和美罗培南/磷霉素联合用药对多重耐药革兰阴性杆菌的体外疗效评估
Mikrobiyol Bul. 2023 Jul;57(3):365-377. doi: 10.5578/mb.20239930.
3
In vitro activity of fosfomycin against bacterial pathogens isolated from urine specimens in Canada from 2007 to 2020: CANWARD surveillance study.2007 年至 2020 年加拿大尿液分离菌的体外药敏研究:CANWARD 监测研究。
J Antimicrob Chemother. 2022 Oct 28;77(11):3035-3038. doi: 10.1093/jac/dkac275.
4
Determination of MIC distribution of arbekacin, cefminox, fosfomycin, biapenem and other antibiotics against gram-negative clinical isolates in South India: a prospective study.印度南部阿贝卡星、头孢米诺、磷霉素、比阿培南及其他抗生素对革兰氏阴性临床分离株的最低抑菌浓度分布测定:一项前瞻性研究。
PLoS One. 2014 Jul 28;9(7):e103253. doi: 10.1371/journal.pone.0103253. eCollection 2014.
5
In Vitro Susceptibility of Multi-Drug Resistant Strains Causing Nosocomial Infections to Fosfomycin. A Comparison of Determination Methods.引起医院感染的多重耐药菌株对磷霉素的体外敏感性。测定方法的比较。
Pathogens. 2021 Apr 23;10(5):512. doi: 10.3390/pathogens10050512.
6
In vitro susceptibility pattern of cephalosporin-resistant Gram-negative bacteria.耐头孢菌素革兰氏阴性菌的体外药敏模式
J Med Assoc Thai. 2008 Oct;91 Suppl 3:S21-7.
7
Evaluation of activity of fosfomycin, and synergy in combination, in Gram-negative bloodstream infection isolates in a UK teaching hospital.评价磷霉素在英国教学医院革兰氏阴性菌血流感染分离株中的活性及其联合用药的协同作用。
J Med Microbiol. 2022 Apr;71(4). doi: 10.1099/jmm.0.001524.
8
Prevalence and Antimicrobial Susceptibility of Bacterial Uropathogens Isolated from Pediatric Patients at Yekatit 12 Hospital Medical College, Addis Ababa, Ethiopia.埃塞俄比亚亚的斯亚贝巴耶卡提12医院医学院从儿科患者中分离出的细菌性尿路病原体的患病率及抗菌药敏性
Int J Microbiol. 2018 Oct 2;2018:8492309. doi: 10.1155/2018/8492309. eCollection 2018.
9
Activity of Fosfomycin and Nitrofurantoin Against Contemporary Pathogens Isolated from Indian Tertiary Care Hospitals.磷霉素和呋喃妥因对印度三级保健医院分离的当代病原体的活性。
Microb Drug Resist. 2021 May;27(5):678-684. doi: 10.1089/mdr.2020.0200. Epub 2020 Oct 13.
10
In vitro activity of the novel siderophore cephalosporin, cefiderocol, in Gram-negative pathogens in Europe by site of infection.在欧洲,根据感染部位,新型铁载体头孢菌素头孢地尔的体外活性对革兰氏阴性病原体的影响。
Clin Microbiol Infect. 2022 Mar;28(3):447.e1-447.e6. doi: 10.1016/j.cmi.2021.07.018. Epub 2021 Jul 21.

引用本文的文献

1
Emerging Concepts for the Treatment of Biofilm-Associated Bone and Joint Infections with IV Fosfomycin: A Literature Review.静脉注射磷霉素治疗生物膜相关骨与关节感染的新观念:文献综述
Microorganisms. 2025 Apr 23;13(5):963. doi: 10.3390/microorganisms13050963.
2
Antimicrobial Treatment Options for Multidrug Resistant Gram-Negative Pathogens in Bone and Joint Infections.骨与关节感染中耐多药革兰氏阴性病原体的抗菌治疗选择
Pathogens. 2025 Feb 1;14(2):130. doi: 10.3390/pathogens14020130.
3
Heteroresistance associated with the production of fosfomycin-resistant inner colonies during disk diffusion testing among a geographically diverse collection of clinical isolates.

本文引用的文献

1
Oral Fosfomycin Formulation in Bacterial Prostatitis: New Role for an Old Molecule-Brief Literature Review and Clinical Considerations.口服磷霉素制剂在细菌性前列腺炎中的应用:老药新角色——文献综述与临床考量
Infect Dis Rep. 2022 Aug 18;14(4):621-634. doi: 10.3390/idr14040067.
2
Evolution and Transmission of Cefiderocol-Resistant Acinetobacter baumannii During an Outbreak in the Burn Intensive Care Unit.在烧伤重症监护病房暴发期间,对头孢地尔耐药鲍曼不动杆菌的进化和传播。
Clin Infect Dis. 2023 Feb 8;76(3):e1261-e1265. doi: 10.1093/cid/ciac647.
3
Can intracellular Staphylococcus aureus in osteomyelitis be treated using current antibiotics? A systematic review and narrative synthesis.
在来自不同地理区域的临床分离株集合中,纸片扩散试验期间与磷霉素耐药内部菌落产生相关的异质性耐药。
JAC Antimicrob Resist. 2025 Feb 20;7(1):dlaf013. doi: 10.1093/jacamr/dlaf013. eCollection 2025 Feb.
4
Insights into the Rising Threat of Carbapenem-Resistant Enterobacterales and Epidemic Infections in Eastern Europe: A Systematic Literature Review.东欧耐碳青霉烯类肠杆菌科细菌及流行感染日益严重威胁的洞察:一项系统文献综述
Antibiotics (Basel). 2024 Oct 17;13(10):978. doi: 10.3390/antibiotics13100978.
5
Resistome in a changing environment: Hotspots and vectors of spreading with a focus on the Russian-Ukrainian War.变化环境中的耐药基因组:传播热点与载体,重点关注俄乌战争
Heliyon. 2024 Jun 8;10(12):e32716. doi: 10.1016/j.heliyon.2024.e32716. eCollection 2024 Jun 30.
6
Evaluation of the susceptibility of clinical isolates of NDM-producing to new antibiotics included in a treatment regimen for infections.评估产NDM临床分离株对感染治疗方案中所包含新抗生素的敏感性。
Front Microbiol. 2024 Apr 5;15:1331628. doi: 10.3389/fmicb.2024.1331628. eCollection 2024.
7
In Vitro Activity of "Old" and "New" Antimicrobials against the Complex.“旧”抗菌药物与“新”抗菌药物对该菌属的体外活性
Antibiotics (Basel). 2024 Jan 26;13(2):126. doi: 10.3390/antibiotics13020126.
8
Use of Newer and Repurposed Antibiotics against Gram-Negative Bacteria in Neonates.新型及重新利用的抗生素在新生儿中用于对抗革兰氏阴性菌的应用。
Antibiotics (Basel). 2023 Jun 19;12(6):1072. doi: 10.3390/antibiotics12061072.
9
Reliability of E-Tests and the Phoenix Automated Method in Assessing Susceptibility to IV Fosfomycin-Comparative Studies Relative to the Reference Method.E测试和Phoenix自动化方法在评估对静脉注射磷霉素敏感性方面的可靠性——相对于参考方法的比较研究
Pathogens. 2023 May 12;12(5):700. doi: 10.3390/pathogens12050700.
目前的抗生素能否治疗骨髓炎中的细胞内金黄色葡萄球菌?一项系统评价与叙述性综合分析。
Bone Res. 2022 Aug 12;10(1):53. doi: 10.1038/s41413-022-00227-8.
4
Cefiderocol: Systematic Review of Mechanisms of Resistance, Heteroresistance and In Vivo Emergence of Resistance.头孢地尔:耐药机制、异质性耐药及体内耐药性产生的系统评价
Antibiotics (Basel). 2022 May 27;11(6):723. doi: 10.3390/antibiotics11060723.
5
The intriguing biology and chemistry of fosfomycin: the only marketed phosphonate antibiotic.磷霉素引人入胜的生物学与化学特性:唯一上市的膦酸酯类抗生素。
RSC Adv. 2019 Dec 19;9(72):42204-42218. doi: 10.1039/c9ra08299a. eCollection 2019 Dec 18.
6
Assessment of In-Vitro Synergy of Fosfomycin with Meropenem, Amikacin and Tigecycline in Whole Genome Sequenced Extended and Pan Drug Resistant : Exploring A Colistin Sparing Protocol.磷霉素与美罗培南、阿米卡星和替加环素在全基因组测序的广泛耐药和泛耐药菌中的体外协同作用评估:探索一种减少黏菌素使用的方案
Antibiotics (Basel). 2022 Jan 25;11(2):153. doi: 10.3390/antibiotics11020153.
7
Synergism of imipenem with fosfomycin associated with the active cell wall recycling and heteroresistance in Acinetobacter calcoaceticus-baumannii complex.亚胺培南与磷霉素协同作用与鲍曼不动杆菌复合体中活跃的细胞壁循环和异质性耐药相关。
Sci Rep. 2022 Jan 7;12(1):230. doi: 10.1038/s41598-021-04303-7.
8
A Real-world Study on Prescription Pattern of Fosfomycin in Critical Care Patients.一项关于危重症患者磷霉素处方模式的真实世界研究。
Indian J Crit Care Med. 2021 Sep;25(9):1055-1058. doi: 10.5005/jp-journals-10071-23958.
9
European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine).欧洲临床微生物学和传染病学会(ESCMID)治疗多重耐药革兰氏阴性杆菌感染的指南(由欧洲重症监护医学学会认可)。
Clin Microbiol Infect. 2022 Apr;28(4):521-547. doi: 10.1016/j.cmi.2021.11.025. Epub 2021 Dec 16.
10
Current and future perspectives in the treatment of multidrug-resistant Gram-negative infections.当前和未来治疗多重耐药革兰氏阴性感染的观点。
J Antimicrob Chemother. 2021 Nov 22;76(Suppl 4):iv23-iv37. doi: 10.1093/jac/dkab352.